Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoHealth (GOCO) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for GoHealth (GOCO) over the last 6 years, with Q3 2025 value amounting to $32.1 million.

  • GoHealth's Cash & Equivalents fell 971.37% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year decrease of 971.37%. This contributed to the annual value of $40.9 million for FY2024, which is 5493.73% down from last year.
  • As of Q3 2025, GoHealth's Cash & Equivalents stood at $32.1 million, which was down 971.37% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, GoHealth's Cash & Equivalents ranged from a high of $215.4 million in Q3 2022 and a low of $14.1 million during Q2 2024
  • In the last 5 years, GoHealth's Cash & Equivalents had a median value of $40.9 million in 2024 and averaged $70.9 million.
  • Over the last 5 years, GoHealth's Cash & Equivalents had its largest YoY gain of 45156.1% in 2023, and its largest YoY loss of 8774.99% in 2023.
  • Over the past 5 years, GoHealth's Cash & Equivalents (Quarter) stood at $84.4 million in 2021, then crashed by 80.48% to $16.5 million in 2022, then surged by 451.56% to $90.8 million in 2023, then tumbled by 54.94% to $40.9 million in 2024, then fell by 21.61% to $32.1 million in 2025.
  • Its Cash & Equivalents was $32.1 million in Q3 2025, compared to $35.6 million in Q2 2025 and $22.2 million in Q1 2025.